HPV and anal cancer risk 10 years later
Part of Cancer, Digestive system, Infections clinical trials.
This study looks at HPV (the virus that can cause anal cancer) and checks if certain types of high-risk HPV are linked to abnormal cells or cancer in the anus, 10 years after joining the IPERGAY trial. It helps researchers understand long-term risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were part of the HPV sub-study in the ANRS IPERGAY trial.
- You have signed the informed consent form.
- You have regular health insurance (not free state medical assistance).
- You are not under legal guardianship or curatorship.
- You agree to allow the use of your data from the original trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how different types of HPV are linked to anal cancer in China. By testing your tumor sample, the researchers hope to better understand what causes anal cancer, which could help guide prevention and treatment.
This trial checks whether tumor samples contain HPV DNA (genetic material from the HPV virus). The goal is to improve detection in anal and cervical cancers, especially in patients planning standard radiation treatment.
This study compares self-sampling (doing your own swab) to a healthcare professional doing the swab for HPV, a virus that can lead to anal cancer. It is for people with HIV on Réunion Island.
This study tests how well a special HPV test (called BD Onclarity™) can find anal cancer or precancer. It is for people at high risk or with known anal abnormalities, and aims to improve early detection.
This study tests a self-collected anal swab for detecting HPV (the virus that can cause anal cancer) in people living with HIV. It aims to see if this simple swab is as accurate as a doctor-collected sample, and may help prevent anal cancer.
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
Hear when a new HPV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.